ATE460923T1 - Lyophilisierung von virosomen - Google Patents

Lyophilisierung von virosomen

Info

Publication number
ATE460923T1
ATE460923T1 AT05824123T AT05824123T ATE460923T1 AT E460923 T1 ATE460923 T1 AT E460923T1 AT 05824123 T AT05824123 T AT 05824123T AT 05824123 T AT05824123 T AT 05824123T AT E460923 T1 ATE460923 T1 AT E460923T1
Authority
AT
Austria
Prior art keywords
virosomes
lyophilization
reconstitution
compositions
methods
Prior art date
Application number
AT05824123T
Other languages
English (en)
Inventor
Rinaldo Zurbriggen
Mario Amacker
Silvia Rasi
Original Assignee
Pevion Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pevion Biotech Ltd filed Critical Pevion Biotech Ltd
Application granted granted Critical
Publication of ATE460923T1 publication Critical patent/ATE460923T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05824123T 2004-12-30 2005-12-21 Lyophilisierung von virosomen ATE460923T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04031022A EP1676569A1 (de) 2004-12-30 2004-12-30 Gefriertrocknung von Virosomen
PCT/EP2005/013829 WO2006069719A2 (en) 2004-12-30 2005-12-21 Lyophilization of virosomes

Publications (1)

Publication Number Publication Date
ATE460923T1 true ATE460923T1 (de) 2010-04-15

Family

ID=34928059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824123T ATE460923T1 (de) 2004-12-30 2005-12-21 Lyophilisierung von virosomen

Country Status (15)

Country Link
US (2) US20080268028A1 (de)
EP (2) EP1676569A1 (de)
CN (1) CN101119707B (de)
AT (1) ATE460923T1 (de)
AU (1) AU2005321496B2 (de)
BR (1) BRPI0519312A2 (de)
CA (1) CA2592437C (de)
DE (1) DE602005020062D1 (de)
DK (1) DK1833465T3 (de)
EA (1) EA011881B1 (de)
ES (1) ES2338908T3 (de)
PL (1) PL1833465T3 (de)
PT (1) PT1833465E (de)
WO (1) WO2006069719A2 (de)
ZA (2) ZA200701577B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20120790T1 (hr) * 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
WO2015000831A1 (en) * 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
CN105899220B (zh) * 2013-12-19 2020-01-10 扬森疫苗与预防公司 改进的病毒体配制品
IL321994A (en) * 2016-02-08 2025-09-01 Univ Johns Hopkins Bioadhesive-dendrimer polymer hydrogel nanoadhesive and its use
CN110913916A (zh) 2017-04-27 2020-03-24 约翰霍普金斯大学 用于血管造影的树状聚合物组合物
CN107375920B (zh) * 2017-06-23 2020-08-11 中农威特生物科技股份有限公司 一种猪繁殖与呼吸综合症病毒-猪流感病毒重构病毒体疫苗及其制备方法和用途
CA3082121C (en) 2017-11-10 2023-01-24 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
JP7391959B2 (ja) * 2018-07-10 2023-12-05 セキラス ピーティーワイ リミテッド 凝集物の除去
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
WO1998052603A2 (en) * 1997-05-23 1998-11-26 Schweiz. Serum- & Impfinstitut Bern An influenza enveloped dna vaccine
US5879685A (en) * 1991-05-08 1999-03-09 Schweiz, Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
JP2005525992A (ja) * 2001-06-25 2005-09-02 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend

Also Published As

Publication number Publication date
DE602005020062D1 (de) 2010-04-29
ZA200705177B (en) 2008-10-29
PT1833465E (pt) 2010-04-08
EA011881B1 (ru) 2009-06-30
EP1833465A2 (de) 2007-09-19
ES2338908T3 (es) 2010-05-13
PL1833465T3 (pl) 2010-08-31
WO2006069719A3 (en) 2006-10-19
EP1676569A1 (de) 2006-07-05
AU2005321496A1 (en) 2006-07-06
AU2005321496B2 (en) 2010-09-16
CN101119707B (zh) 2011-06-15
US20080268028A1 (en) 2008-10-30
BRPI0519312A2 (pt) 2009-01-06
ZA200701577B (en) 2008-10-29
WO2006069719A2 (en) 2006-07-06
CN101119707A (zh) 2008-02-06
DK1833465T3 (da) 2010-05-31
CA2592437C (en) 2013-06-18
CA2592437A1 (en) 2006-07-06
EP1833465B1 (de) 2010-03-17
US20140072616A1 (en) 2014-03-13
EA200701306A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
ZA200705177B (en) Lyophilization of virosomes
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
NO20071127L (no) Triazoloftalaziner
NO345046B1 (no) Oral doseringsform
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CR20130455A (es) Composiciones para el tratamiento de tumores
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DE602005020611D1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
BRPI0414599A (pt) pirrol-indóis substituìdos
EA200700702A1 (ru) Аналоги локсапина и способы их применения
BRPI0414463A (pt) ácidos heteroarilbenzofuránicos substituìdos
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
DK1572959T3 (da) Hybridpolymerase-fremgangsmåder og -sammensætninger
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA200401032A1 (ru) Антиинфарктные молекулы
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1833465

Country of ref document: EP